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Abstract
Soybean MON 87751 was developed through Agrobacterium tumefaciens-mediated transformation to
provide protection certain speciﬁc lepidopteran pests by the expression of the Cry1A.105 and Cry2Ab2
proteins derived from Bacillus thuringiensis. The molecular characterisation data and bioinformatic
analyses did not identify issues requiring assessment for food and feed safety. None of the compositional,
agronomic and phenotypic differences identiﬁed between soybean MON 87751 and the conventional
counterpart required further assessment. The GMO Panel did not identify safety concerns regarding the
toxicity and allergenicity of the Cry1A.105 and Cry2Ab2 proteins as expressed in soybean MON 87751,
and found no evidence that the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of
soybean MON 87751. The nutritional impact of soybean MON 87751-derived food and feed is expected
to be the same as those derived from the conventional counterpart and non-GM commercial reference
varieties. The GMO Panel concludes that soybean MON 87751, as described in this application, is
nutritionally equivalent to and as safe as the conventional counterpart and the non-GM soybean
reference varieties tested, and no post-market monitoring of food and feed is considered necessary. In
the case of accidental release of viable soybean MON 87751 seeds into the environment, soybean
MON 87751 would not raise environmental safety concerns. The post-market environmental monitoring
plan and reporting intervals are in line with the intended uses of soybean MON 87751. In conclusion,
soybean MON 87751, as described in this application, is as safe as its conventional counterpart and the
tested non-GM soybean reference varieties with respect to potential effects on human and animal health
and the environment.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following the submission of application EFSA-GMO-NL-2014-121 under Regulation (EC) No 1829/2003
from Monsanto, the Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority (GMO
Panel) was asked to deliver a scientiﬁc opinion on the safety of the genetically modiﬁed (GM) soybean
(Glycine max (L.) Merr.) MON 87751 (Unique Identiﬁer MON-87751-7). The scope of application EFSA-
GMO-NL-2014-121 is for import and processing, and food and feed uses of soybean MON 87751 within
the European Union (EU), but excludes cultivation in the EU.
The GMO Panel evaluated soybean MON 87751 with reference to the scope and appropriate principles
described in Regulation (EU) 503/2013 and its guidelines for the risk assessment of GM plants. The
evaluation addressed the following components of the risk assessment: the molecular characterisation of
the inserted DNA and analysis of the expression of the corresponding proteins; the comparative analyses
of compositional, agronomic and phenotypic characteristics; the safety of the newly expressed proteins
and of the whole food and feed with respect to potential toxicity, allergenicity and nutritional
characteristics; the environmental risk assessment and the post-market environmental monitoring
(PMEM) plan.
The molecular characterisation data establish that soybean MON 87751 contains a single insert
consisting of one copy of the cry1A.105 and cry2Ab2 expression cassettes. Bioinformatic analyses of
the sequences encoding the newly expressed proteins and other open reading frames present within
the insert or spanning the junctions between the insert and genomic DNA, do not indicate signiﬁcant
similarities to toxins and allergens. The stability of the inserted DNA and of the introduced insect
resistance trait is conﬁrmed over several generations. The Cry1A.105 and Cry2Ab2 proteins were
expressed and the methodology used to quantify their levels is considered adequate. The protein
characterisation data comparing the structural, biochemical and functional properties of plant- and
microbe-derived Cry1A.105 and Cry2Ab2 proteins indicate that these proteins are equivalent and the
microbe-derived proteins can be used in the safety studies.
The comparative assessment of compositional, agronomic and phenotypic characteristics does not
identify differences between soybean MON 88751 and its conventional counterpart requiring further
assessment. The GMO Panel did not identify safety concerns regarding the toxicity and allergenicity of
the Cry1A.105 and Cry2Ab2 proteins, as expressed in soybean MON 87751 and found no evidence that
the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean MON 87751.
The nutritional impact of soybean MON 87751-derived food and feed is expected to be the same as
those derived from the conventional counterpart and non-GM commercial reference varieties. The GMO
Panel concludes that soybean MON 87751, as described in this application, is nutritionally equivalent to
and as safe as the conventional counterpart and the non-GM soybean reference varieties tested, and
no post-market monitoring of food and feed is considered necessary.
Considering the introduced traits, the outcome of the comparative analysis, and the routes and
levels of exposure, the GMO Panel concludes that soybean MON 87751 would not raise safety
concerns in the event of accidental release of viable GM soybean seeds into the environment. The
PMEM plan and reporting intervals are in line with the intended uses of soybean MON 87751.
The literature searches did not identify any relevant publications. In the context of PMEM, the
applicant should improve future literature searches according to the GMO Panel recommendations.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2014-
121, additional information provided by the applicant, scientiﬁc comments submitted by the Member
States and relevant scientiﬁc publications. The GMO Panel concludes that soybean MON 87751, as
described in this application, is as safe as its conventional counterpart and the tested non-GM soybean
reference varieties with respect to potential effects on human and animal health, and the environment.
Assessment of soybean MON 87751
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1. Introduction
The scope of application EFSA-GMO-NL-2014-121 is for food and feed uses, import and processing
of soybean MON 87751 and does not include cultivation in the European Union (EU).
Soybean MON 87751 was developed to confer resistance against certain lepidopteran pests. This is
achieved by the expression of the cry1A.105 and cry2Ab2 genes from Bacillus thuringiensis (Bt).1
1.1. Background
On 8 October 2014, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2014-121 for authorisation of soybean
MON 87751 (Unique Identiﬁer MON-87751-7), submitted by Monsanto Europe (hereafter referred to as
the applicant) within the framework of Regulation (EC) No 1829/2003 on GM food and feed.2
After receiving application EFSA-GMO-NL-2014-121, and in accordance with Articles 5(2)(b) and 17(2)
(b) of Regulation (EC) No 1829/2003, EFSA informed the Member States and the European Commission,
and made the summary of the application available to the public on the EFSA website.3 EFSA initiated a
formal review of the application to check compliance with the requirements laid down in Articles 5(3) and
17(3) of Regulation (EC) No 1829/2003. On 22 December 2014, EFSA received additional information
requested under completeness check on 25 November 2014. On 22 January 2015, EFSA declared the
application valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to Member States and the European Commission, and
consulted nominated risk assessment bodies of Member States, including national Competent Authorities
within the meaning of Directive 2001/18/EC4 following the requirements of Articles 6(4) and 18(4) of
Regulation (EC) No 1829/2003 to request their scientiﬁc opinion. Member States had three months after
the opening of the Member State commenting period (until 4 July 2015) to make their opinion known.
The GMO Panel requested additional information from the applicant on 29 January 2015 (EURL-
JRC), 31 March 2015, 5 June 2015, 2 December 2015, 23 December 2015, 11 February 2016, 23
February 2016, 18 March 2016, 23 May 2016, 20 July 2016, 7 December 2016, 23 December 2016,
10 February 2017, 8 March 2017, 14 March 2017, 3 May 2017, 6 July 2017, 2 August 2017,
25 September 2017, 23 November 2017, 4 December 2017 and 7 March 2018. EFSA received
the requested information on 12 March 2015 (EURL-JRC), 1 July 2015, 15 July 2015, 9 December
2015, 8 February 2016, 24 February 2016 and 14 March 2016, 22 March 2016, 29 March 2016,
21 July 2016, 22 September 2016, 20 December 2016, 23 December 2016, 11 April 2017, 15 May
2017, 19 May 2017, 31 May 2017, 14 August 2017, 22 August 2017, 23 November 2017, 4 December
2017, 30 January 2018 and 3 May 2018, respectively. The applicant also spontaneously submitted
additional information on 20 April 2016, 2 May 2017, 5 October 2017 and 22 December 2017.
In the context of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
In giving its scientiﬁc opinion on soybean MON 87751 to the European Commission, Member States
and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003,
EFSA has endeavoured to respect a time limit of 6 months from the acknowledgement of the valid
application. As additional information was requested by the GMO Panel, the time limit of six months was
extended accordingly, in line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this Scientiﬁc Opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc risk assessment of soybean MON 87751 for
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of
Regulation (EC) No 1829/2003.
1 Dossier Part II – Section 1.2.2.1.
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2014-00719
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.03.2001, p. 1–38.
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Where applicable, any conditions or restrictions for the placing on the market and/or speciﬁc
conditions or restrictions for use and handling, including post-market monitoring requirements based on
the outcome of the risk assessment and, in the case of GMOs or food and feed containing or consisting of
GMOs, conditions for the protection of particular ecosystems/environment and/or geographical areas
should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its Scientiﬁc Opinion, the GMO Panel took into account application EFSA-GMO-NL-
2014-121, additional information provided by the applicant, scientiﬁc comments submitted by the
Member States and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of soybean MON 87751 for food and feed uses,
import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003.
The GMO Panel took into account Regulation (EU) No 503/2013 and the appropriate principles
described in its guidelines for the risk assessment of GM plants and derived food and feed (EFSA GMO
Panel, 2011a), the environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010a) and
the post-market environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The GMO Panel took into account the criteria included in the EFSA Scientiﬁc Committee (2011)
guidance on conducting repeated-dose 90-day oral toxicity study in rodents on whole food and feed
for GMO risk assessment’ and in the ‘Explanatory statement for its applicability (EFSA, 2014), to
perform the assessment of the 90-day feeding studies provided.
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion5 and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Systematic literature review6
The GMO Panel assessed the applicant’s literature searches on soybean MON 87751, which include
a scoping review, according to the guidelines given in EFSA (2010, 2017).
A systematic literature review as referred to in Regulation (EU) No 503/2013 has not been provided
in support of the risk assessment of application EFSA-GMO-NL-2014-121. Based on the outcome of the
scoping review, the GMO Panel agrees that there is limited value in undertaking a systematic review
for soybean MON 87751 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO Panel considers
that future searches on soybean MON 87751 could be improved. The GMO Panel therefore recommends
the applicant to:
– ensure that enough search term variation is used (covering possible synonyms, related
terms, acronyms, spelling variants, old and new terminology, brand and generic names, lay
and scientiﬁc terminology, common typos, translation issues);
– use truncation consistently;
– include controlled vocabulary (subject indexing) in the searches when available, and where
subject headings are available use both free-text terms and controlled vocabulary in the
searches;
5 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2018-00505
6 Dossier: Part II – Section 7; additional information: 8/2/2016, 20/12/2016 and 22/12/2017.
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– adapt the search to the size of the identiﬁed publications (and thus not combine search sets
when one of the search sets already yields only a small number of publications);
– assess the relevance and risk assessment implications of publications retrieved via searches
beyond electronic bibliographic databases.
The literature searches did not identify any relevant publications on soybean MON 87751.
3.2. Molecular characterisation
3.2.1. Transformation process and vector constructs7
Soybean MON 87751 was developed by Agrobacterium tumefaciens (also known as Rhizobium
radiobacter)-mediated transformation of meristem tissues derived from germinated soybean seeds
(Glycine max (L.) Merr.) using a disarmed strain AB30 containing the PV-GMIR13196 vector. The
PV-GMIR13196 vector contained two T-DNAs, T-DNA I with the cry2Ab2 and cry1A.105 expression
cassettes between the right and left borders which confer insect resistance. T-DNA II contained the
aadA and splA expression cassettes between the right and left borders, which were used for the
selection of transformed plants. Although both T-DNAs were initially inserted during transformation,
they were not genetically linked and T-DNA II was eliminated by crossing, therefore only T-DNA I is
present in soybean MON 87751 and is described below.
The cry1A.105 expression cassette contains the following genetic elements: the promoter, leader
and chloroplast targeting sequences from an Arabidopsis thaliana rbcS gene family encoding the small
subunit ats1A; the codon-optimised cry1Ab, cry1F and cry1Ac coding sequences assembled to produce
the Cry1A.105 chimeric protein, and the 3’ untranslated region of the pt1 gene from Medicago
truncatula.
The cry2Ab2 expression cassette contains the following genetic elements: the promoter, leader and
intron sequences from the act2 gene from A. thaliana; the CTP2 chloroplast targeting sequence of the
shkG gene from A. thaliana; the codon-optimised cry2Ab2 gene from B. thuringiensis; and the 3’
untranslated region of the mt gene from Oryza sativa.
The vector backbone contains elements necessary for the maintenance and selection of the plasmid
in bacteria.
3.2.2. Transgene constructs in the GM plant
Molecular characterisation of soybean MON 87751 was performed by next generation sequencing
(NGS) and junction sequence analysis (JSA), polymerase chain reaction (PCR) and DNA sequence
analysis in order to determine insert copy number, size and organisation of the inserted sequences,
and to conﬁrm the absence of plasmid backbone sequences.8 The approach used is acceptable in
terms of coverage and sensitivity.
NGS/JSA of the whole genome indicates that soybean event MON 87751 contains a single insert,
which consists of a single copy of T-DNA I in the same conﬁguration as in the PV-GMIR13196
transformation vector. NGS/JSA also indicates the absence of vector backbone and T-DNA II
sequences.
The nucleotide sequence of the entire insert of soybean MON 87751 together with 1334 bp of the
5’ and 1187 bp of the 3’ ﬂanking regions were determined. The results are in line with those shown by
the NGS/JSA analyses. The insert of 10119 bp is identical to the T-DNA I of PV-GMIR13196. A
comparison of the ﬂanking regions sequences with the pre-insertion locus indicates a 1 bp insertion
and a 7 bp deletion at the insertion site as well as a 16 bp deletion in the 5’ ﬂanking region. The
possible interruption of known endogenous soybean genes by the insertion in event MON 87751 was
evaluated by bioinformatic analyses of the pre-insertion locus and of the genomic sequences ﬂanking
the insert.9,10 The results of these analyses do not indicate the interruption of any known endogenous
genes in soybean MON 87751.
The results of segregation (see below) and bioinformatic analyses establish that the insert is
located in the nuclear genome.
7 Dossier: Part II – Section 1.2.1.
8 Dossier: Part II – Section 1.2.2.2; additional information: 29/3/2016.
9 Dossier Part II – Section 1.2.2.2(e).
10 Additional information: 9/12/2015 and 19/5/2017.
Assessment of soybean MON 87751
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2018;16(8):5346
Updated bioinformatic analyses of the amino acid sequences of the newly expressed Cry1A.105 and
Cry2Ab2 proteins reveals no signiﬁcant similarities to known toxins and allergens.9 In addition, updated
bioinformatic analyses of the newly created open reading frames (ORFs) within the insert or spanning
the junctions between the insert and genomic DNA do not indicate signiﬁcant similarities to toxins and
allergens.9,10
In order to assess the possibility for horizontal gene transfer by homologous recombination, the
applicant performed a sequence identity analysis of the inserted regions of bacterial origin in soybean
MON 87751.10,11 The likelihood and potential consequences of plant-to-bacteria gene transfer are
described in Section 3.5.1.2.
3.2.3. Protein characterisation and equivalence
Soybean MON 87751 expresses two new proteins, Cry1A.105 and Cry2Ab2.
Given the technical restraints in producing large enough quantities for safety testing from plants,
these proteins were recombinantly produced in Escherichia coli. Prior to safety studies, a set of
biochemical methods was employed to demonstrate the equivalence between soybean- and microbe-
derived proteins. Puriﬁed proteins from these sources were characterised and compared in terms of
their physicochemical, structural and functional properties.
Cry1A.105 characterisation and equivalence.12 Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and western blot analysis show that plant- and microbe-derived Cry1A.105
proteins have the expected molecular weight of ~133 kDa and are comparably immunoreactive to
Cry1A.105 protein speciﬁc antibodies. Glycosylation detection analysis demonstrates that none of the
Cry1A.105 proteins were glycosylated. Amino acid sequence analysis by mass spectrometry methods
shows that both proteins match the deduced sequence as deﬁned by the cry1A.105 gene. In addition,
N-terminal sequencing analysis shows that the N-terminus of the soybean-derived Cry1A.105 protein is
intact and four amino acids originating from the chloroplast transit peptide (CTP) are also present.
These data are consistent with the microbe-derived Cry1A.105 protein, designed to contain also the
four amino acids from the CTP. Functional equivalence was demonstrated by an insect feeding
bioassay which shows that both proteins have comparable insecticidal activity.
Cry2Ab2 characterisation and equivalence.13 SDS-PAGE and western blot analysis show that plant-
and microbe-derived Cry2Ab2 proteins have the expected molecular weight of ~62 kDa and are
comparably immunoreactive to Cry2Ab2 protein speciﬁc antibodies. Glycosylation detection analysis
demonstrates that none of the Cry2Ab2 proteins were glycosylated. Amino acid sequence analysis by
mass spectrometry methods shows that both proteins match the deduced sequence as deﬁned by the
inserted cry2Ab2 gene. In addition, N-terminal sequencing analysis shows that the ﬁrst 15 amino acids
of the N terminus of the soybean-derived Cry2Ab2 protein are truncated. These data are consistent
with the microbe-derived Cry2Ab2 protein designed to also start at amino acid 16. Functional
equivalence was demonstrated by an insect feeding bioassay which shows that both proteins have
comparable insecticidal activity.
The protein characterisation data comparing the structural, biochemical and functional properties of
plant- and microbe-derived Cry1A.105 and Cry2Ab2 proteins, indicate that these proteins are
equivalent. Therefore, the GMO Panel accepts the use of the Cry1A.105 and Cry2Ab2 proteins
produced in bacteria for the safety studies.
3.2.4. Information on the expression of the insert14
Protein levels of Cry1A.105 and Cry2Ab2 were analysed by enzyme-linked immunosorbent assay
(ELISA) in material harvested from replicated ﬁeld trials across ﬁve locations in the USA during the
2012 growing season. Samples analysed included leaves (V3–V4, V5–V7, R2–R3, R4), root (R6), forage
(R6), pollen/anther (R2, collected only from one site) and seeds (R8). The mean values, standard
deviations and ranges of protein expression levels in seeds and forage of the Cry1A.105 and Cry2Ab2
proteins are summarised in Table 1.
11 Dossier: Part II – Section 1.2.2.5.
12 Dossier: Part II – Section 1.4.1.1(a); additional information: 9/12/2015.
13 Dossier: Part II – Section 1.4.1.1(b).
14 Dossier: Part II – Section 1.2.2.3.
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3.2.5. Inheritance and stability of inserted DNA15
Genetic stability of the soybean MON 87751 insert was assessed by NGS/JSA for ﬁve generations
and PCR-based segregation analysis from three generations. The results indicate that all the plants
tested retain the single copy of the insert and ﬂanking regions, which were stably inherited in
subsequent generations. The results support the presence of a single insertion, segregating in a
Mendelian fashion.
3.2.6. Conclusion on molecular characterisation
The molecular characterisation data establish that soybean MON 87751 contains a single insert
consisting of one copy of the cry1A.105 and cry2Ab2 expression cassettes. Bioinformatic analyses of
the sequences encoding the newly expressed proteins and other ORFs present within the insert or
spanning the junctions between the insert and genomic DNA do not indicate signiﬁcant similarities to
toxins and allergens. The stability of the inserted DNA and of the introduced insect resistance trait is
conﬁrmed over several generations. The Cry1A.105 and Cry2Ab2 proteins are expressed and the
methodology used to quantify their levels is considered adequate. The protein characterisation data
comparing the structural, biochemical and functional properties of plant- and microbe-derived
Cry1A.105 and Cry2Ab2 proteins indicate that these proteins are equivalent and the microbe-derived
proteins can be used in the safety studies.
3.3. Comparative analysis
3.3.1. Choice of comparator and production of material for the comparative
assessment16
Application EFSA-GMO-NL-2014-121 presents data on agronomic and phenotypic characteristics, as
well as on forage and seed composition of soybean MON 87751 derived from a ﬁeld trial study
performed at nine sites in the USA in 2012, and from studies performed under environmentally
controlled conditions (Table 2).
Table 1: Means, standard deviations and ranges of protein levels in seeds (n = 20) and forage
(n = 20) (lg/g dry weight) from soybean MON 87751
Tissue (Developmental stage) Cry1A.105 Cry2Ab2
Seeds (R8) 2.40(a)  0.50(b)
(1.70–3.20)(c)
4.0  0.77
(2.60–5.10)
Forage (R6) 230.0  91.0
(110.0–440.0)
14.0  2.20
(11.0–18.0)
(a): Mean.
(b): Standard deviation.
(c): Range.
Table 2: Overview of comparative assessment studies with soybean MON 87751 provided in
application EFSA-GMO-NL-2014-121
Study focus Study details Comparator
Commercial non-GM soybean
reference varieties(b)
Agronomic and
phenotypic analysis
Field trials, 2012, USA, nine
locations(a)
A3555 Twenty(c)
Pollen characteristics study
under controlled conditions
A3555 Four(d)
Seed germination study under
controlled conditions
A3555 Twelve(e)
15 Dossier: Part II – Section 1.2.2.4; additional information: 22/08/2017 and 23/11/2017.
16 Dossier: Part II – Section 1.3.1 and 1.3.2.1.
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The ﬁeld trial study was conducted in typical soybean growing areas of the USA17, representing
regions of diverse agronomic practices and environmental conditions. At each site, the following
materials were grown in a randomised complete block design with four replicates: soybean MON 87751,
a non-GM comparator (soybean A3555), and four non-GM soybean reference varieties. All materials were
treated (sprayed) with required maintenance pesticides according to local requirements. Depending on
the focus of the study, the number of locations from which the data were collected and reference
varieties used differs (see Table 2).
The comparator used in the comparative assessment studies was a non-GM soybean variety
(A3555) with the same genetic background to that of soybean MON 87751 (as documented by the
pedigree), and is considered the conventional counterpart.
3.3.2. Statistical analysis of ﬁeld trial data18
The statistical analysis of the agronomic, phenotypic and compositional data from the 2012 ﬁeld
trial study followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a) and
complied with Regulation (EU) No 503/2013. This includes the application of a difference test
(between the GM soybean and its conventional counterpart) and an equivalence test (between the GM
soybean and the set of non-GM soybean reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).19
3.3.3. Agronomic and phenotypic analysis20
3.3.3.1. Agronomic and phenotypic characteristics tested under ﬁeld conditions
The agronomic and phenotypic endpoints evaluated in the ﬁeld trials were: early stand count, days
to 50% ﬂowering, plant lodging, pod shattering, plant height, ﬁnal stand count, seed moisture,
100 seed weight and yield. Visually observable responses to naturally occurring diseases, abiotic stress
and arthropod damage were also recorded in order to provide indications of altered stress responses
of soybean MON 87751 as compared with its conventional counterpart.
The test of difference shows statistically signiﬁcant differences between soybean MON 87751 and
its conventional counterpart for days to 50% ﬂowering, plant lodging, plant height and seed moisture.
The test of equivalence shows that all these endpoints were equivalent to the non-GM soybean
reference varieties (equivalence category I).
Study focus Study details Comparator
Commercial non-GM soybean
reference varieties(b)
Compositional
analysis
Field trials, 2012, USA, eight
locations(a)
A3555 Nineteen(f)
Non-GM: non-genetically modiﬁed.
(a): Except at one location for the agronomic and phenotypic analysis (Miami, OH) data were obtained from the same ﬁeld trials.
(b): Four different varieties were grown at each location of the ﬁeld trials.
(c): Hoffman H419, DWIGHT, Crows C2804, Garst 3585N, Midland 363, Crows C3908, NuPride 3202, C3211N, Midwest Genetics
G2712, A3244, Stewart SB3819, Wilken 3316, Hoffman HS387, LG C3540, Stine 3300-0, A3525, Lewis 391, WILLIAMS 82,
Stewart SB3454, Crows C37003N.
(d): Garst 3585N, FS 3591, eMerge 348TC, Midland 363.
(e): LG C3540, Crows C37003N, A3244, NuPride 3202, DWIGHT, Crows C2804, Garst 3585N, Midland 363, Stine 3300-0, A3525,
Hoffman HS387, Wilken 3316.
(f): DWIGHT, Crows C2804, Garst 3585N, Midland 363, Crows C3908, NuPride 3202, C3211N, Midwest Genetics G2712, A3244,
Stewart SB3819, Wilken 3316, Hoffman HS387, LG C3540, Stine 3300-0, A3525, Lewis 391, WILLIAMS 82, Stewart SB3454,
Crows C37003N.
17 The ﬁeld sites were located in Jackson (AR), Story (IA), Jefferson (IA), Champaign (IL), Pawnee (KS), Perquimans (NC),
Merrick (NE), Miami (OH) and Lehigh (PA). In the ﬁeld trial located in Miami only agronomic and phenotypic characteristics
were evaluated.
18 Dossier: Part II – Section 1.3.2.2.
19 The results of the equivalence test are categorised into four possible outcomes: category I (indicating full equivalence);
category II (equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence);
and category IV (indicating non-equivalence).
20 Dossier: Part II – Section 1.3.5; additional information: 15/7/2015, 24/2/2016, 14/3/2016 and 22/3/2016.
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3.3.3.2. Agronomic and phenotypic characteristics tested under controlled conditions
Seed characteristics
The applicant reported data on seed characteristics of soybean MON 87751 (Table 2). Seeds were
incubated under controlled conditions at six different temperature regimes. The endpoints analysed
were the numbers of normal germinated seeds, abnormal germinated seeds, hard seeds, dead seeds
and ﬁrm swollen seeds. No statistically signiﬁcant differences are observed between soybean
MON 87751 and its conventional counterpart, except for % normal and abnormal germinated seeds at
one temperature regime. For all endpoints and temperature regimes, the observed values in soybean
MON 87751 are within the range of those observed in the non-GM reference varieties.
Although the applicant refers to seed dormancy when discussing the generated data on soybean
MON 87751 seeds characteristics, no data on induced seed dormancy were supplied. The GMO
Panel considers that only the conclusions on germination of F1 seeds of soybean MON 87751 are
substantiated by the provided data.
Pollen characteristics
The applicant reported data on pollen characteristics of soybean MON 87751 (Table 2). The
endpoints analysed were pollen diameter and viability via the Alexander stain method. No signiﬁcant
differences between soybean MON 87751 and its conventional counterpart for pollen diameter and
stain uptake are observed.
3.3.4. Compositional analysis21
Soybean MON 87751 seeds and forage harvested from the ﬁeld trial study in the USA in 2012
(Table 2) were analysed for 74 different constituents (seven in forage22 and 67 in seeds23), including
the key constituents recommended by the OECD (2012). For 14 fatty acids,24 more than 50% of the
observations were below the limit of quantiﬁcation.
The statistical analysis was applied to the remaining 58 constituents (six in forage and 52 in seeds); a
summary of the outcome of the test of difference and the test of equivalence is presented in Table 3.25
The combination of the test of difference and the test of equivalence could be applied to the 58
endpoints, with the following results:
For soybean MON 87751, statistically signiﬁcant differences with the conventional counterpart are
identiﬁed for 14 endpoints in seeds26 and three in forage.27 All the endpoints fall under equivalence
categories I or II.
21 Dossier: Part II – Section 1.3.4; additional information: 15/7/2015.
22 Crude protein, crude fat, ash, moisture, carbohydrates by calculation, acid detergent ﬁbre (ADF) and neutral detergent ﬁbre (NDF).
23 Protein, total fat, ash, moisture, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), calcium,
phosphorus, alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, caprylic acid (8:0), capric acid (10:0), lauric acid (12:0),
myristic acid (14:0), myristoleic acid (14:1), pentadecanoic acid (15:0), pentadecenoic acid (15:1), palmitic acid (16:0),
palmitoleic acid (16:1), heptadecanoic acid (17:0), heptadecenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic
acid (18:2), linolenic acid (18:3), c-linolenic acid (18:3), arachidic acid (20:0), eicosenoic acid (20:1), eicosadienoic acid
(20:2), eicosatrienoic acid (20:3), arachidonic acid (20:4), behenic acid (22:0), a-tocopherol, phylloquinone, daidzein,
genistein, glycitein, lectin, phytic acid, rafﬁnose, stachyose, trypsin inhibitor, Gly m 1, Gly m 3, Gly m 4, Gly m 5, Gly m 6, Gly
m 8, Gly m Bd 28 K and Gly m Bd 30 K.
24 Caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, pentadecanoic acid, pentadecenoic acid, palmitoleic acid,
heptadecanoic acid, heptadecenoic acid, c-linolenic acid, eicosadienoic, eicosatrienoic acid, and arachidonic acid.
25 Moisture was measured for seed and forage and used only for conversion of components to dry weight, but were not
statistically analysed as such.
26 Total protein, carbohydrates by calculation, glycine, methionine, proline, calcium, phosphorus, stearic acid, oleic acid, linoleic
acid, arachidic acid, behenic acid, phylloquinone and rafﬁnose.
27 Neutral detergent ﬁbre (NDF), carbohydrates by calculation and total fat.
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The GMO Panel assessed all signiﬁcant differences between soybean MON 87751 and its conventional
counterpart, taking into account the potential impact on the plant metabolism and the natural variability
observed for the set of non-GM commercial reference varieties. No endpoints showing signiﬁcant
differences between soybean MON 87751 and its conventional counterpart and falling under category
III/IV are identiﬁed.
3.3.5. Conclusion on comparative analysis
The GMO Panel concludes that none of the agronomic, phenotypic and compositional changes
identiﬁed with respect to the conventional counterpart and the non-GM soybean reference varieties
need further assessment regarding food and feed safety and their environmental impact.
3.4. Food and feed safety assessment
3.4.1. Effects of processing
Soybean MON 87751 will undergo existing production processes used for conventional soybean. No
novel production process is envisaged. Therefore, processing of soybean MON 87751 into food and feed
products is not expected to result in products being different from those derived from non-GM varieties.
3.4.2. Inﬂuence of temperature and pH on newly expressed proteins
3.4.2.1. Effect of temperature on newly expressed proteins28
The thermal stability of the microbe-derived Cry1A.105 protein was evaluated for 15 or 30 min at
25, 37, 55, 75 and 95°C, and the insecticidal activity and integrity of the protein was assessed by an
insect feeding bioassay and SDS-PAGE, respectively. Heating at 75°C or above (for 15 or 30 min)
results in the complete loss of the Cry1A.105 activity. SDS-PAGE indicates a detectable reduction in the
Cry1A.105 band intensity when the protein is heated at 95°C for 30 min.
The thermal stability of the microbe-derived Cry2Ab2 protein was evaluated for 15 or 30 min at 25,
37, 55, 75 and 95°C and the insecticidal activity and integrity of the protein was assessed by an insect
feeding bioassay and SDS-PAGE, respectively. Heating at 55°C or above (for 15 or 30 min) results in
the complete loss of the Cry2Ab2 activity. SDS-PAGE indicates a signiﬁcant reduction in the Cry2Ab2
band intensity when the protein is heated at 75 or 95°C for 15 or 30 min.
3.4.2.2. Effect of pH on newly expressed proteins29
The effect of pH on the intactness of the microbe-derived Cry1A.105 was assessed by SDS-PAGE
analysis at three pH conditions; pH 10.3 (the protein’s storage buffer), pH 1.2 and 7.5. The data show
that the puriﬁed Cry1A.105 protein remains intact at these pH solutions.
Table 3: Outcome of the comparative compositional analysis in grains and forage of soybean
MON 87751. The table shows the number of endpoints in each category
Test of difference(a)
Not different Signiﬁcantly different
Test of equivalence(b) Category I/II 41 17(c)
Category III/IV – –
Not categorised – –
Total endpoints 58
(a): Comparison between soybean MON 87751 and its conventional counterpart.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Endpoints with signiﬁcant differences between soybean MON 87751 and its conventional counterpart falling in equivalence
category I-II. For seeds: total fat, carbohydrates by calculation, stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2),
arachidic acid (C20:0), behenic acid (C22:0), glycine, proline, protein, calcium, phosphorus, rafﬁnose and phylloquinone. For
forage: total fat, NDF and carbohydrates by calculation.
28 Dossier: Part II – Section 1.4.1.3a.
29 Dossier: Part II – Section 1.4.1.3b.
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The effect of pH on the intactness of the microbe-derived Cry2Ab2 was assessed by SDS-PAGE
analysis at three pH conditions; pH 11.2 (the protein’s storage buffer), pH 1.2 and 7.5. The data show
that the puriﬁed Cry2Ab2 protein remains intact at these pH solutions.
3.4.3. Toxicology
3.4.3.1. Testing of the newly expressed proteins
The two proteins, Cry1A.105 and Cry2Ab2, newly expressed in soybean MON 87751 have been
extensively characterised (Section 3.2.3).
The Cry1A.105 protein was previously assessed by the GMO Panel (e.g. EFSA, 2008)30 and no
safety concerns for humans and animals were identiﬁed. Updated bioinformatic analysis does not
reveal similarities of the Cry1A.105 protein to known toxins causing toxicity to humans and animals
(except for speciﬁc lepidopteran pests). The GMO Panel is not aware of any new information that
would change the previous conclusion of the risk assessment that the Cry1A.105 protein does not raise
safety concerns.
The Cry2Ab2 protein was previously assessed by the GMO Panel (e.g. EFSA, 2008)31 and no safety
concerns for humans and animals were identiﬁed. Updated bioinformatic analysis does not reveal
similarities of the Cry2Ab2 protein to known toxins causing toxicity to humans and animals (except for
speciﬁc lepidopteran pests). The GMO Panel is not aware of any new information that would change the
previous conclusion of the risk assessment that the Cry2Ab2 protein does not raise safety concerns.
Based on scientiﬁc knowledge, no synergistic or antagonistic interactions between the two proteins
newly expressed in soybean MON 87751 which could raise safety concerns for food and feed are expected.
The applicant provided studies on Cry1A.105 and Cry2Ab2 proteins from bacterial recombinant
systems, which were considered equivalent to the plant-produced proteins (Section 3.2.3).
In vitro degradation studies32
The resistance of the microbe-derived Cry1A.105 and Cry2Ab2 proteins (E. coli produced MON 87751
Cry1A.105 and Cry2Ab2 proteins) to degradation by pepsin were investigated in solutions at pH ~ 1.2 in
two independent studies. The integrity of the test proteins in samples of the incubation mixture taken at
various time points was analysed by SDS-PAGE gel electrophoresis followed by protein staining or by
Western blotting. No intact Cry1A.105 or Cry2Ab2 proteins were observed after 30 seconds of incubation.
By protein staining analysis, a peptide fragment of 60 kDa was observed in samples of Cry1A.105 after
30 s of incubation but it was not seen at the 2 min incubation time point. In addition, low-molecular-
weight fragments of ~ 4–5 kDa observed in samples of Cry1A.105 or Cry2Ab2 completely disappeared
after 20 min or after 2 min of incubation, respectively. By western blot analysis, none of these fragments
were immunologically reactive to a polyclonal antibody against either Cry1A.105 or Cry2Ab2.
Furthermore, the applicant performed a sequential digestion test based on a brief digestion (2 min)
in a pepsin resistance test followed by digestion in so called simulated intestinal ﬂuid (SIF) according
to a method previously described (USP, 1995) in which SIF designates a mixture of proteolytic
enzymes known as pancreatin. The purpose of such test was to better understand the digestive fate of
Cry1A.105 protein and, particularly, to address the digestibility of the transiently stable ~ 5 kDa
fragment visible in the early incubation time points of the pepsin degradation study. Under this
scenario, the small fragment was completely digested within 30 seconds of SIF exposure.
In addition, the applicant also performed a standalone degradation study of Cry1A.105 and
Cry2Ab2 proteins in SIF. The GMO Panel notes that the resistance to degradation by standalone SIF is
currently not speciﬁcally required by either Regulation (EU) No 503/2013, EFSA guidance document
(EFSA GMO Panel, 2011a) or Codex Alimentarius (2009). Due to the intrinsic limitations of such
standalone SIF degradation study for the food and feed safety of newly expressed proteins, it is not
considered in the overall safety assessment.
The main outcomes of the in vitro degradation studies detailed above are in line with those
described for Cry1A.105 and Cry2Ab2 proteins previously assessed by the GMO Panel (EFSA, 2008).
30 The amino acid sequence of Cry1A.105 in soybean MON 87751 differs from that previously assessed in maize MON 89034
(EFSA, 2008) by the presence of four additional amino acid residues at the N terminus. However, the remaining of the
Cry1A.105 amino acid sequence in soybean MON 87751 is identical to that in maize MON 89034.
31 The amino acid sequence of Cry2Ab2 in soybean MON 87751 differs from that previously assessed in maize MON 89034
(EFSA, 2008) by the lack of the ﬁrst 18 amino acid residues at the N terminus. However, the remaining of the Cry2Ab2 amino
acid sequence in soybean MON 87751 is identical to that in maize MON 89034.
32 Dossier: Part II – Section 1.5.1.3.
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Acute oral toxicity testing33
For compliance with Article 6 of Regulation (EU) No 503/2013, the applicant spontaneously
submitted four acute toxicity studies in mice with Cry1a.105 and Cry2Ab2 proteins which were
evaluated by the GMO Panel.
A microbe-derived Cry1a.105 protein was administrated in two separate studies at the doses of
2,000 mg/kg body weight (bw) or 5,000 mg/kg bw to male and female Crl:CD1(ICR) mice. No adverse
effects related to the Cry1a.105 protein were observed.
A microbe-derived Cry2Ab2 protein was administrated in two separate studies at the dose of
2,000 mg/kg bw or 5,000 mg/kg bw to male and female Crl:CD1(ICR) mice. No adverse effects related
to the Cry2Ab2 protein were observed.
28-day repeated dose toxicity study34
For compliance with Article 6 of Regulation (EU) No 503/2013, the applicant spontaneously
submitted two 28-day repeated dose toxicity studies in mice with Cry1a.105 and Cry2Ab2 proteins
which were evaluated by the GMO Panel.
Cry1a.105 protein
The applicant provided a 28-day oral repeated dose toxicity study in mice, conducted in accordance
with OECD TG 407 (2008) and in compliance with the principles of Good Laboratory Practice (GLP).
Groups of singly caged Crl:CD1(ICR) mice (16 per sex per group, approximately seven weeks old at
study start) were administered by gavage for 28 days the Cry1A.105 protein (in bicarbonate buffer
solution) at targeted nominal doses of 10, 100 or 1,000 mg/kg bw per day (low-, mid- and high-dose
Cry1A.105 protein groups) or bovine serum albumin (BSA) at a targeted nominal dose of 1000 mg/kg
bw per day (BSA control group). No vehicle control group was included in the study.
The batch of the test substance contained 78% (wt/wt) of a recombinant Cry1A.105 protein
produced in E. coli). Detailed information of the protein characterisation was provided with the
certiﬁcate of analysis.35 This protein has a molecular weight of 131.1 kDa.
Three dosing formulations of Cry1A.105 protein and BSA were prepared and provided as frozen
aliquots for daily use. Samples of these formulations were used for concentration conﬁrmation,
homogeneity and stability analyses.
Feed and water were provided ad libitum. During the treatment period, the animals were checked
twice daily for mortality and clinical signs. Detailed clinical observations were conducted on all animals
before treatment and weekly during the treatment period. Ophthalmoscopy was performed before the
start and during the last week of the treatment period. Individual body weights were recorded before
treatment and weekly thereafter; body weight gains were calculated relative to the ﬁrst day of treatment
(day 0). Feed consumption was determined weekly. At the end of the treatment period, blood samples
were taken for haematology and clinical chemistry analyses from up to ten animals (randomly selected)
per sex and group; blood samples for coagulation analysis were taken from the remaining ﬁve or six
animals per sex and group. All animals surviving the treatment period were sacriﬁced and underwent a
detailed necropsy with determination of organ weights. Animals found dead or euthanised in extremis
during the treatment period also underwent a detailed necropsy examination. Organs and tissues from
those animals assigned to haematology and clinical chemistry analyses in the high-dose Cry1A.105
protein group, the BSA control group and those found dead or euthanized in extremis were subjected to
a comprehensive histopathological examination. Histopathology of gross lesions was conducted
throughout groups. A pathology peer review was conducted.
For all continuous endpoints mean, standard deviation and the number of animals were reported
for each treatment group. The original statistical analysis provided was based on one-way ANOVA
model followed, in case of statistically signiﬁcant (p < 0.05) intergroup variance, by a Dunnett’s test to
compare the Cry1A.105-treated groups to the BSA-treated group. Due to the study design including a
high-dose (1,000 mg/kg bw per day) BSA administration as the only control, the GMO Panel asked for
a new statistical analysis assessing effects in the 1,000 mg/kg bw per day Cry1A.105 protein group as
compared to the 1,000 mg/kg bw per day BSA group only. In response to this EFSA request36, body
weight, body weight change, feed consumption, clinical pathology and organ weight data were
33 Additional information: 20/12/2016.
34 Additional information: 5/10/2017.
35 The purity of the test substance was taken into account in the formulation.
36 Additional information received on 3/5/2018.
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analysed, by sex, using two-sample t-test at 5% signiﬁcance level to compare high-dose test group
(1,000 mg/kg bw per day, Group 4) to the BSA-treated group. Histopathological ﬁndings data were
analysed using one-sided Fisher’s exact test at 5% signiﬁcance level.
The Cry1A.105 and BSA proteins concentration, homogeneity and stability were conﬁrmed.
No test substance-related mortality was observed. One male of the BSA control group was found
dead on day 13 of the study; the cause of death was not established. Three animals given the Cry1A.105
protein at a dose of 1000 mg/kg bw per day were found dead or were sacriﬁced for humane reasons
(one male on day 3 and two females on day 14 and 17) as a consequence of gavage errors.
No test diet-related clinical signs and ophthalmoscopic ﬁndings were observed.
A statistically signiﬁcant increase in mean ﬁnal body weight (day 28) and cumulative body weight
gain (days 0–7 and 0–28) were observed in females given the Cry1A.105 protein, compared to the
BSA control group (~ 6%). Due to the low magnitude of the increase in the ﬁnal body weight, the
GMO Panel does not consider these changes as adverse.
Haematological analysis showed a statistically signiﬁcant decrease in the red blood cell count
(~ 9%), haemoglobin concentration (~ 7%) and haematocrit (~ 8%), and an increase in the red blood
cell distribution width (~ 8%) in males given the Cry1A.105 protein, compared to the BSA control
group. These differences were small, not associated with test substance-related changes in related
parameters (e.g. reticulocyte count, gross pathology and histopathology of spleen and bone marrow)
and therefore, the GMO Panel does not consider these effects as being adverse.
A statistically signiﬁcant increase in mean absolute neutrophil count (~ 47%) was observed in males
given the Cry1A.105 protein, compared to the BSA control group. Although substantial, this difference
was not associated with test substance-related changes in related parameters (e.g. percentage of
neutrophils, white blood cell count, histopathology of thymus and bone marrow). Therefore, the GMO
Panel does not consider this isolated ﬁnding as an adverse effect.
A statistically signiﬁcant increase in mean absolute LUC37 count (~ 100%) was observed in males
given the Cry1A.105, compared to the BSA control group. Although substantial, this increase was not
associated with an increase in the percentage of LUC or changes in related endpoints of the white
blood cell population (e.g. lymphocytes, mononuclear cells). Moreover, no histopathological ﬁndings
potentially related to increased LUC count was reported (e.g. histopathology of reticuloendothelial,
haematopoietic and lymphoid tissues). Therefore, the GMO Panel does not consider this isolated
ﬁnding as an adverse effect.
Clinical chemistry analysis showed a statistically signiﬁcant decrease in mean albumin (~ 6%),
albumin/globulin (A/G) ratio (~ 5%), sodium (~ 1.7%) and chloride (~ 1.3%) concentrations in males
given the Cry1A.105 protein, compared to the BSA control group. These differences were minimal and
therefore, the GMO Panel does not consider these changes to be adverse.
Organ weight determinations showed a statistically signiﬁcant increase in mean spleen weight
(absolute, 28%; relative to body weight, 27%) and relative liver weight (~ 6%) in males given the
Cry1A.105 protein, compared to the BSA control group. No test substance-related histologic changes were
noted in these organs and therefore, the GMO Panel does not consider these changes as adverse effects.
A statistically signiﬁcant decrease in mean adrenal gland weights (absolute, 12%; relative to body
weight, 17%; and relative to brain weight, 8%) was observed in females given the Cry1A.105 protein,
compared to the BSA control group. No test substance-related histologic changes were noted in these
organs and therefore, the GMO Panel does not consider these changes as adverse effects.
Macroscopic examinations performed at necropsy on all animals revealed no gross pathological
ﬁndings related to the administration of the Cry1A.105 protein. Microscopic examinations of selected
organs and tissues identiﬁed no test substance-related differences in the incidences and severity of the
histopathological ﬁndings between the groups.
The GMO Panel notes the following deviations from OECD TG 407 requirements: coagulation
examinations were based on a relatively low number of evaluable samples (in most of the cases below
the minimum requirement of ﬁve animals/gender per group). Functional observational battery (FOB)
and locomotor activity tests were not performed.
Regarding the coagulation analysis, the GMO Panel considered that the integrated assessment of
related parameters (e.g. no difference in the platelet count or in the spleen and bone marrow
histopathology between groups) indicates that an effect on coagulation parameters is unlikely. The
37 Large unstained cells, i.e. large peroxidase-negative cells that cannot be characterised further as large lymphocytes, ‘virocytes’
or stem cells.
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GMO Panel therefore concludes that this is not a major deviation compromising the safety assessment
of the Cry1A.105 protein.
Regarding the lack of FOB and locomotor activity tests (tests performed to identify potential
neurotoxicity of a test substance), the GMO Panel used a weight of evidence approach to exclude
potential neurotoxic effects of the Cry1A.105 protein: (1) in this 28-day study, no test substance-
related ﬁndings were noted in the daily clinical examinations or in the detailed clinical examinations
(performed approximately weekly, including removal from the home cage); (2) no test substance-
related effects were seen in the acute oral toxicity studies in mice given 2,000 or 5,000 mg Cry1A.105
protein/kg bw; (3) no similarity of the Cry1A.105 protein to known neurotoxicants was identiﬁed in
bioinformatic analysis; (4) according to current knowledge, there is no indication of neurotoxicity for
Cry proteins (e.g. EFSA GMO Panel, 2016a–c, 2017a,b). The GMO Panel therefore considers that the
lack of FOB and locomotor activity tests is not a major deviation compromising the safety assessment
of the Cry1A.105 protein.
The GMO Panel concludes that no adverse effects are observed in this mouse 28-day toxicity study
on Cry1A.105 protein at the highest dose tested (1,000 mg/kg bw per day).
Cry2Ab2 protein
The applicant provided a 28-day oral repeated dose toxicity study in mice, conducted in accordance
with OECD TG 407 (2008) and in compliance with the GLP principles.
Groups of singly caged Crl:CD1(ICR) mice (16/sex per group, approximately seven weeks old at
study start) were administered by gavage for 28 days the Cry2Ab2 protein (in carbonate-bicarbonate
buffer solution) at targeted nominal doses of 10, 100, or 1,000 mg/kg bw per day (low-, mid- and
high-dose Cry2Ab2 protein groups) or BSA in the same vehicle at a targeted nominal dose of
1,000 mg/kg bw per day (BSA control group). No vehicle control group was included in the study.
The two batches of the test substance contained 71% and 76% (wt/wt) of a recombinant Cry2Ab2
protein produced in E. coli. Detailed information on the protein characterisation was provided with the
certiﬁcate of analysis.34 This protein has a molecular weight of 59.5 kDa.
Three dosing formulations of Cry2Ab2 protein and BSA were prepared and provided as frozen
aliquots for daily use. Samples of these formulations were used for concentration conﬁrmation,
homogeneity and stability analyses.
Feed and water were provided ad libitum. During the treatment period, the animals were checked
twice daily for mortality and clinical signs. Detailed clinical observations were conducted on all animals
before treatment and weekly during the treatment period. Ophthalmoscopy was performed before the
start and during the last week of the treatment period. Individual body weights were recorded before
treatment and weekly thereafter; body weight gains were calculated relative to the ﬁrst day of
treatment (day 0). Feed consumption was determined weekly. At the end of the treatment period,
blood samples were taken for haematological and clinical chemistry analyses from up to ten animals
(randomly selected) per sex and group; blood samples for coagulation analysis were taken from the
remaining six animals per sex and group. All animals surviving the treatment period were sacriﬁced
and underwent a detailed necropsy with determination of organ weights. Animals found dead during
the treatment period also underwent a detailed necropsy examination. Organs and tissues from those
animals assigned to haematological and clinical chemistry analyses in the high-dose Cry2Ab2 protein
group, the BSA control group and those found dead were subjected to a comprehensive
histopathological examination. Histopathology of gross lesions was conducted throughout groups. A
pathology peer review was conducted.
For all continuous endpoints mean, standard deviation and the number of animals were reported
for each treatment group. The original statistical analysis provided was based on one-way analysis of
variance (ANOVA) model followed, in case of statistically signiﬁcant (p < 0.05) intergroup variance, by
a Dunnett’s test to compare the Cry2Ab2-treated groups to the BSA-treated group. Due to the study
design including a high-dose (1,000 mg/kg bw per day) BSA administration as the only control, the
GMO Panel asked for a new statistical analysis assessing effects in the 1,000 mg/kg bw per day
Cry2Ab2 protein group as compared to the 1,000 mg/kg bw per day BSA group only. In response to
this EFSA request,35 body weight, body weight change, feed consumption, clinical pathology and organ
weight data were analysed, by sex, using two-sample t-test at 5% signiﬁcance level to compare high-
dose test group (1,000 mg/kg bw per day, Group 4) to the BSA-treated group. Histopathological
ﬁndings data were analysed using one-sided Fisher’s exact test at 5% signiﬁcance level.
The Cry2Ab2 and BSA protein concentration, homogeneity and stability were conﬁrmed.
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No test substance-related mortality was observed. One male of the BSA control group and one
female given the test substance at 100 mg/kg bw per day were found dead during the study, as a
consequence of gavage errors.
No test diet-related clinical signs and ophthalmoscopic ﬁndings were observed.
A statistically signiﬁcant decrease in mean feed consumption (g/animal/day, ~ 16%) was observed
in males given the Cry2Ab2 protein, compared to the BSA control group, during study days 7 to 14.
This decrease was not associated with differences in the mean ﬁnal and mean cumulative body
weights and thus not toxicologically relevant.
Haematological analysis showed a statistically signiﬁcant increase in mean absolute neutrophil count
(~ 150%) in females given the Cry2Ab2 protein, compared to the BSA control group. Although the
difference was substantial, it was not associated with test substance-related changes in related
parameters (e.g. percentage of neutrophils, white blood cell count, histopathology of thymus and bone
marrow). Therefore, the GMO Panel does not consider this isolated ﬁnding as an adverse effect.
A statistically signiﬁcant decrease in mean corpuscular volume (MCV) (~ 3.6%) and increase in mean
corpuscular haemoglobin concentration (~ 3%) were also observed in females given the Cry2Ab2 protein,
compared to the BSA control group. The differences in these calculated parameters were minimal and not
associated with test substance-related changes in related parameters (e.g. red blood cell count,
haemoglobin concentration, haematocrit), and is therefore not considered as adverse effects by the GMO
Panel.
Clinical chemistry analysis showed a statistically signiﬁcant decrease in mean triglyceride levels
(~ 23%) in males given the Cry2Ab2 protein, compared to the BSA control group. The GMO Panel
considers this small change as not being adverse. A statistically signiﬁcant decrease in mean A/G ratio
(~ 8%) was observed in females given the Cry2Ab2 protein, compared to the BSA control group. The
difference was small and therefore, the GMO Panel does not consider this change as an adverse effect.
Organ weight determinations showed a statistically signiﬁcant increase in mean weights (relative to
ﬁnal body weights only) of brain (~ 4%), epididymides (~ 10%) and spleen (~ 17%) in males given the
Cry2Ab2 protein, compared to the BSA control group. No test substance-related histological changes were
noted in these organs, and therefore, the GMO Panel does not consider these changes as adverse effects.
Macroscopic examinations performed at necropsy on all animals revealed no gross pathological
ﬁndings related to the administration of the Cry2Ab2 protein. Microscopic examinations of selected
organs and tissues identiﬁed no test substance-related differences in the incidences and severity of the
histopathological ﬁndings between the groups.
The GMO Panel noted the following deviations from OECD TG 407 requirements: coagulation
examinations were performed on six animals per gender per group, except for high-dose females (four
animals examined). FOB and locomotor activity tests were not performed.
Regarding the coagulation analysis, the GMO Panel considered that the integrated assessment of
related parameters (e.g. no difference in the platelet count or in the spleen and bone marrow
histopathology between groups) indicates that an effect on coagulation parameters is unlikely. The
GMO Panel therefore concludes that this is not a major deviation compromising the safety assessment
of the Cry2Ab2 protein.
Regarding the lack of FOB and locomotor activity tests (tests performed to identify potential
neurotoxicity of a test substance) the GMO Panel used a weight of evidence approach to exclude
potential neurotoxic effects of the Cry2Ab2 protein: (1) in this 28-day study no test substance-related
ﬁndings were noted in the daily clinical examinations or in the detailed clinical examinations (performed
approximately weekly, including removal from the home cage); (2) no test substance-related effects
were seen in the acute oral toxicity studies in mice given 2,000 or 5,000 mg Cry2Ab2 protein/kg bw;
(3) no similarity of the Cry2Ab2 protein to known neurotoxicants was identiﬁed in bioinformatic analysis;
(4) according to current knowledge, there is no indication of neurotoxicity for Cry proteins (e.g. EFSA
GMO Panel, 2016a–c, 2017a,b). The GMO Panel therefore considers that the lack of FOB and locomotor
activity tests is not a major deviation compromising the safety assessment of the Cry2Ab2 protein.
The GMO Panel concluded that no adverse effects is observed in this mouse 28-day toxicity study
on Cry2Ab2 protein at the highest dose tested (1,000 mg/kg bw per day).
3.4.3.2. Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identiﬁed in soybean
MON 87751. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
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3.4.3.3. Information on altered levels of food/feed constituents
None of the differences identiﬁed in seed and forage composition between soybean MON 87751
and its conventional counterpart (Section 3.3.4) require further assessment.
3.4.3.4. Testing of the whole genetically modiﬁed food and feed
No substantial modiﬁcations in the composition of soybean MON 87751, no indication of possible
unintended effects relevant for food/feed safety were identiﬁed. Therefore, animal studies on the food/
feed derived from soybean MON 87751 are not necessary (EFSA GMO Panel, 2011a). In accordance
with Regulation (EU) No 503/2013 the applicant provided a 90-day oral repeated-dose toxicity study
on whole food and feed from soybean MON 87751 in rats. Animal feeding studies in broilers and
channel catﬁsh fed diets containing soybean MON 87751 were also provided in compliance with Article
6 of Regulation (EU) No 503/2013. All these studies are evaluated by the GMO Panel.
90-day feeding study in rats38
Pair-housed Crl:CD(SD) rats (16/sex per group) were allocated to two groups using a randomised
complete block design with eight replications. Groups were fed test or control diets containing
approximately 30% (w/w) toasted defatted meal from soybean MON 87751 (test item) or from the
conventional counterpart (control material), respectively. The study provided was adapted from
OECD TG 408 and complying with the GLP principles.
Event-speciﬁc PCR analysis on seeds39 prior to processing into meal conﬁrmed the molecular
identity of soybean MON 87751 seeds and the lack of soybean MON 87751 contamination in the
conventional counterpart. Both test item and control materials were analysed for proximates, amino
acids, minerals, antinutrients and pesticides.
Balanced diets40 were prepared according to the speciﬁcations for PMI Certiﬁed Rodent LabDiet
#5002, with a soybean meal inclusion rate of 30% (w/w).
Stability of the test and control materials was not tested; however in accordance to product expiration
standards declared by the diet manufacturer, the constituents of the diets are considered stable for the
duration of the treatment. There are currently no practical analytical methods available to determine
homogeneity, and concentration of toasted defatted soybean meal in the formulated diets. Diet
preparation procedures and regular evaluations of the mixing methods by surrogate analytes guaranteed
their homogeneity and the proper concentration of the test or control material in them.
Feed and water were provided ad libitum.
Animals were checked twice daily for mortality and clinical signs. Detailed physical examinations
were conducted on all animals pre-treatment and then weekly during the dosing period, and on the
day of the scheduled necropsy. Individual body weights were recorded pretreatment and then weekly
during the dosing period and on the day prior to the scheduled necropsy. Feed consumption (per
cage) was determined weekly during the study.
Ophthalmoscopy and FOB data and locomotor activity were recorded on all animals pre-treatment
and at the end of the study (week 12). Clinical pathology (i.e. haematology, clinical chemistry and
coagulation, urine analyses) and necropsy examination with organs weighing were conducted at the
end of the treatment period on all animals. The animals were fasted overnight prior to blood collection
while in metabolism cages for urine collection. Organs and tissues from all sacriﬁced animals as well as
gross lesions were subjected to a detailed histopathological examination. Upon completion of the
histopathologic assessment of all tissues, histopathology was reviewed by a peer review pathologist.
Mean, median, standard deviation, min and max were reported for all continuous endpoints for each
group/sex and per period or time as appropriate. The applicant performed a power analysis per gender,
using a prespeciﬁed effect sizes41 for eight endpoints42 with a 5% level of signiﬁcance. For all selected
endpoints the power estimates were greater than 99%, with the exception of absolute lymphocytes
(80% for males and 60% for females), and body weight (80% for males and 88% for females). The cage
or the individual animal was considered the experimental unit according to the corresponding estimate of
38 Dossier: Part II – Section 1.4.4.1
39 Additional information: 20/4/2016.
40 Additional information: 20/4/2016 and 21/7/2016.
41 Deﬁned on the basis of six previous studies: WIL-50283 (Kirkpatrick, 2005), WIL-50296 (Kirkpatrick, 2007), WIL-50297
(Kirkpatrick, 2007), WIL-50333 (WIL-WIL-50370 (Kirkpatrick, 2010) and additional information 22/9/2016.
42 Eight endpoints were selected: absolute lymphocytes, alkaline phosphatase, body weight, cholesterol, creatinine, urea
nitrogen, kidney weight, liver weight.
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cage effect. The in-life and terminal body weights/gain, organ weights, feed consumption/efﬁciency and
clinical pathology and functional observations when appropriate, parameters were checked for
homogeneity and normality,43 analysed with ANOVA and tested using a t-tests. Finally, outcome
proportions of incidence of functional observations were analysed with Fisher’s exact test. In response to
a request from the GMO Panel44 the difference between test and control groups and associated 95%
conﬁdence interval were also presented in terms of standardised effect size (i.e. normalised to standard
deviation45). The goodness-of-ﬁt was evaluated by visual examination of residual plots and histograms.46
Based on this evaluation the models were considered appropriate.
All animals survived the treatment period. No test diet related clinical signs and ophthalmoscopic
ﬁndings were observed.
No statistically signiﬁcant differences in mean body weights and in mean body weight gains are
observed between animals fed the test and control diets. No treatment-related differences in feed
consumption are noted.
No statistically signiﬁcant differences in FOB and locomotor activity parameters are observed
between animals fed the test and control diets at the end of the study, with the exception of tail pinch
response and hindlimb footsplay, in males fed the test diet, compared to control. These were the only
changes among the parameters examined and therefore not considered to be test substance related.
Statistically signiﬁcant lower mean absolute neutrophil count and mean absolute monocyte count
were observed, respectively, in males and in females fed the test diet, as compared to the corresponding
control group. The GMO Panel considers these isolated ﬁndings not to be treatment-related.
Statistically signiﬁcant lower mean red blood cell count, haemoglobin concentration, reticulocyte
number (absolute reticulocytes), and higher MCV were observed in females fed the test diet compared
to control. These ﬁndings were not associated with changes in haematopoietic tissue histopathology
(e.g. sternum bone marrow and spleen) and therefore are not considered toxicologically relevant.
Statistically signiﬁcant decreases in mean albumin (2.5%) and total protein (3%) were observed in
males fed the test diet. These minimal differences are not considered to be toxicologically relevant.
Lower mean alkaline phosphatase values were observed in females fed the test diet compared the
respective controls. This ﬁnding was not associated with changes in related endpoints (e.g. liver
histopathology) and is not considered toxicologically relevant.
Statistically signiﬁcant higher urine mean speciﬁc gravity and a slightly lower mean pH value were
observed in females fed test diet, compared to controls. In the absence of changes related to renal
pathology, these ﬁndings are not considered toxicologically relevant.
No statistically signiﬁcant differences in organ weight were observed among male and female rats
fed test diets and controls, except for a lower mean absolute brain weight (3.2%) in males and a
lower mean relative liver weight (3%) in females fed the test diets, compared to controls. These
changes are not considered to be adverse because of their magnitude and because the decrease in
the relative liver weight is not associated with changes in related endpoints (e.g. liver histopathology).
No treatment-related gross lesions or microscopic ﬁndings were noted in organs or tissues.
Sporadic histopathological ﬁndings are considered compatible with the spontaneous background
pathology of rats of this strain and age.
The GMO Panel concludes that no soybean MON 87751-related adverse effects were observed in
this study.
The GMO Panel notes that the applicant tested only one dose level. However, the dose tested was
close to the highest possible without inducing nutritional imbalance according to the current
knowledge, and in accordance to the limit test dose as described in OECD TG 408. Therefore, this is
not considered to affect the above conclusions.
A second 90-day feeding study in rats on defatted toasted meal from soybean MON 87551 was
submitted. The GMO Panel notes that balanced diets were prepared including test and control
materials stored for more than one year, without any check for stability.47 For this reason, the GMO
Panel does not further consider this study in the assessment.
43 Normality and heterogeneity assumptions were checked by visual examination of residual plots and histogram. No extreme
violations of the assumptions were observed.
44 Additional information received on 22/9/2016 and 20/12/2016.
45 Additional information 20/12/2016.
46 Additional information 11/4/2017.
47 Additional information received: 31/5/2017.
Assessment of soybean MON 87751
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2018;16(8):5346
42-day broiler study48
A total of 800 (400 per sex) one-day old chicken broilers (Cobb 9 Cobb 500) were randomly
allocated to eight dietary groups with 100 chicks per treatment (ten pens per treatment, half for each
sex, ten birds per pen) and fed balanced diets49 containing up to 35%50 soybean meal from soybean
MON 87751 (test diet), the conventional counterpart A3555 (control diet) or one of the six reference
varieties Midwest Genetics G2712, Stewart SB3454, Hoffman H387, Williams 82, Gateway 505, Horizon
Genetics H5310N (reference diets). Diets (as crumbled pellets or pellets) and water were offered
ad libitum. No statistically signiﬁcant differences between the groups fed test and control diets were
observed in the majority of growth performance and carcass parameters: mortality (2.5%), ﬁnal body
weight, weight gain, feed to gain ratio, and yield of pre-chill organs and post-chilled carcass and
cuttable parts (absolute and relative weights). A higher breast weight and lower thigh weight
percentages were observed in the test group, compared to the control group; these ﬁndings, since not
associated to changes in the respective absolute weights and in carcass yield, were not considered
adverse. Some statistically signiﬁcant differences (i.e. adjusted feed to gain ratio and breast meat,
thigh and drum weight percentages) were observed between the test group and one or two out of six
reference groups. Because the differences were not observed between the test group and the majority
of the reference groups, they are not considered relevant.
The GMO Panel concludes that administration of diets containing up to 35% soybean meal
MON 87751 to broilers does not cause adverse effects and that the measured performance endpoints
were similar between groups fed balanced diets containing GM and non-GM soybean (conventional
counterpart and references).
8-week channel ﬁsh study51
A total of 600 channel catﬁsh (sex undetermined) were randomly allocated to six dietary groups
with 100 catﬁshes per treatment (ﬁve aquaria per treatment, twenty ﬁshes per aquaria) and fed
balanced diets formulated as sinking pellets containing approximately 45% soybean meal from
soybean MON 87751 (test diet), the conventional counterpart A3555 (control diet) or one of the four
reference varieties Midwest Genetics G2712, Stewart SB3454, Hoffman H387, Gateway 505 (reference
diets). No mortality and no abnormal behaviours were observed among ﬁshes in any aquarium during
the study. There were no statistically signiﬁcant differences in overall weight gain per ﬁsh, total diet
consumption per ﬁsh, or diet conversion ratio among ﬁsh fed the test, control and reference diets.
The GMO Panel concludes that administration of balanced diets containing up to 45% soybean
meal MON 87751 to channel catﬁsh does not cause adverse effects and that the measured
performance endpoints were similar between groups fed balanced diets containing GM and non-GM
soybean (conventional counterpart and references).
3.4.4. Allergenicity
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised persons and on whether the transformation may have altered the
allergenic properties of the modiﬁed plant.
3.4.4.1. Assessment of allergenicity of the newly expressed proteins52
A weight-of-evidence approach was followed, taking into account all the information obtained on
the newly expressed protein, as no single piece of information or experimental method yield sufﬁcient
evidence to predict allergenicity (Codex Alimentarius 2009; EFSA GMO Panel, 2011a; Regulation (EU)
No 503/2013).
The cry1A.105 and cry2Ab2 genes originate from B. thuringiensis, which is not considered to be an
allergenic source.
Updated bioinformatic analyses53 of the amino acid sequences of the Cry1A.105 and Cry2Ab2
proteins, using the criterion of 35% identity in a sliding window of 80 amino acids, revealed no
48 Additional information received: 8/2/2016.
49 Starter (0–21 days) and grower/ﬁnisher (22–42 days) diets.
50 ~ 35% in starter diets; ~ 31% in grower/ﬁnisher diets.
51 Additional information received 8/2/2016.
52 Dossier: Part II – Section A1.5.1, A1.3.4.2 and additional information: 20/12/2016 and 15/5/2017.
53 Additional information: 19/5/2017.
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signiﬁcant similarities to known allergens. In addition, the applicant performed analyses searching for
matches of eight contiguous identical amino acid sequences between the Cry1A.105 and Cry2Ab2
proteins and known allergens, which conﬁrmed the outcome of the previous bioinformatic analyses.
The studies on resistance of the Cry1A.105 and Cry2Ab2 proteins to degradation by pepsin have
been described in Section 3.4.3.1.
The GMO Panel has previously evaluated the safety of the Cry1A.105 and Cry2Ab2 proteins in
maize MON 89034 and no concerns on allergenicity were identiﬁed (EFSA, 2008).
For adjuvanticity, proteins derived from B. thuringiensis (Bt proteins) have been suggested to
possess adjuvant activity based on laboratory animal studies on Cry1Ac when applied at relatively high
doses (e.g. Vazquez et al., 1999). The GMO Panel has previously evaluated the safety of the
Cry1A.105 and Cry2Ab2 proteins and no concerns on adjuvanticity in the context of the applications
assessed were identiﬁed (EFSA, 2008). From the limited knowledge and experimental evidence
available, the Panel does not ﬁnd indications that the presence of the Bt proteins at the levels
expressed in seeds from soybean MON 87751 might act as adjuvants with the potential to enhance a
speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic reaction. With
regard to forage, in which the levels of the Cry1A.105 and Cry2Ab2 proteins were higher than in
seeds, the GMO Panel has no indications that these Cry proteins may have an adjuvant effect in
animals fed forage.
In the context of the present application, the GMO Panel considers that there are no indications that
the newly expressed Cry1A.105 and/or Cry2Ab2 proteins in soybean MON 87751 may be allergenic.
3.4.4.2. Assessment of allergenicity of the whole GM plant or crop54
Soybean is considered to be a common allergenic food55 (OECD, 2012). Therefore, any potential
change in the endogenous allergenicity of the GM plant should be assessed (Regulation (EU)
No 503/2013). For such assessment, the applicant included in the comparative analysis speciﬁc
allergens relevant for soybean (Section 3.3.4) that were measured by speciﬁc ELISA methods, which
have been previously considered as acceptable (EFSA GMO Panel, 2010c; Fernandez et al., 2013; Selb
et al., 2017). The applicant also referred to the Kunitz trypsin inhibitor as a potential soybean allergen,
which is an antinutrient and as such it is also an endpoint already assessed in the compositional
analysis (see Section 3.3.4). These allergens were selected based on the list of potential soybean
allergens described in the pertinent OECD document (OECD, 2012) and a scientiﬁc rational supporting
such selection was provided by the applicant and considered acceptable by the GMO Panel. No
changes in the levels of endogenous allergens raising concern are identiﬁed by the GMO Panel.
Furthermore, the applicant provided two additional studies not requested by the GMO Panel. First,
an investigation of the endogenous allergenicity comparing whole protein extracts of soybean
MON 87751 and its conventional counterpart by gel electrophoresis analysis was conducted. The
identity of bands/spots corresponding to speciﬁc soybean allergens were conﬁrmed by mass
spectrometry and their intensity were assessed by image analysis. No relevant changes in the intensity
of the bands/spots between the protein extracts of soybean MON 87751 and its conventional
counterpart were identiﬁed. Second, the IgE-binding capacity of whole protein seed extracts from
soybean MON 87751, its conventional counterpart and different reference soybean varieties was also
investigated using sera from four individuals allergic to soybean by EAST (enzyme allergosorbent test).
Whole proteins in extracts from soybean MON 87751, the conventional counterpart and the reference
varieties used had similar reactivity to the sera from the four allergic individuals.
In the context of this application, the GMO Panel considers that there is no evidence that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean MON 87751 when
compared with that of the conventional counterpart and the non-GM commercial reference soybean
varieties tested.
54 Dossier: Part II – Section 1.5.2 and additional information: 20/12/2016 and 15/5/2017.
55 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC,
Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and
Commission Regulation (EC) No 608/2004.
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3.4.5. Dietary exposure assessment to endogenous and new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure to Cry1A.105
and Cry2Ab2 proteins produced in soybean MON 87751.
3.4.5.1. Human dietary exposure56
Only acute dietary exposure estimates to Cry1A.105 and Cry2Ab2 proteins were provided by the
applicant. Dietary exposure was estimated across different European countries on different population
groups: young population (toddlers, other children) and adult population (adolescents, adults, elderly
and very elderly).
For the purpose of estimating dietary exposure, the levels of Cry1A.105 and Cry2Ab2 proteins in
soybean MON 87751 seeds were derived from the 2012 USA ﬁeld trial study (see Table 1 in
Section 3.2.4); mean values of 2.1 lg/g and 3.6 lg/g (fresh weight) were used for Cry1A.105 and
Cry2Ab2, respectively. Since no speciﬁc consumption data were available on consumption of commodities
containing MON 87751 soybean, a conservative scenario with 100% replacement of conventional
soybean by the GM soybean was considered. Consumption ﬁgures for the relevant commodities were
retrieved by the applicant from the available summary statistics of the EFSA Comprehensive European
Food Consumption Database.57 The EFSA consumption database contains information on food
consumption data at individual level from the most recent national dietary surveys in different EU Member
States (EFSA, 2011; Huybrechts et al., 2011; Merten et al., 2011). Soybean oil was excluded from the
assessment since no proteins are expected to be present in the oil.
For acute exposure estimations, the applicant used the protein content in the different soybean
derived commodities to estimate the concentration of Cry1A.105 and Cry2Ab2 proteins in the
consumed foods. This is considered a conservative approach as no losses of Cry1A.105 and Cry2Ab2
are assumed during processing. For each population group, the food commodity among consumers
only (95th or 97.5th percentile depending on the number of consumers; EFSA 2011) leading to the
highest acute exposure was selected. In ‘Other children’ (3–10 years), the highest acute exposure was
estimated as 6.2 lg/kg bw day and 10.6 lg/kg bw day for Cry1A.105 and Cry2Ab2, respectively,
following the consumption of soya drink. In adults (18–65 years), the highest acute exposure was
estimated as 17.9 lg/kg bw day and 30.7 lg/kg bw day for Cry1A.105 and Cry2Ab2, respectively,
following the consumption of meat imitates (textured soy protein). The use of the highest acute
consumption for only one food commodity could slightly underestimate the dietary exposure to
Cry1A.105 and Cry2Ab2 proteins in certain population groups.
The GMO Panel estimated chronic dietary exposure to Cry1A.105 and Cry2Ab2 proteins, since this was
not provided by the applicant. Individual consumption data of the relevant food commodities were
retrieved from the EFSA Comprehensive European Food Consumption Database, using dietary surveys
with at least two days consumption and covering a total of 19 European countries.58 Different recipes and
processing factors were considered to estimate the amount of soybean in the consumed commodities
before assigning Cry1A.105 and Cry2Ab2 levels to the relevant commodities.59 No losses in Cry1A.105
and Cry2Ab2 during processing were considered. For protein Cry1A.105, the highest mean chronic dietary
exposure in the young population was estimated in toddlers (1–3 years) with 0.36 lg/kg bw day, while
the highest 95th percentile exposure was in ‘Other children’ (3–10 years) with 0.60 lg/kg bw day.
Corresponding highest estimates in adults were 0.05 lg/kg bw day and 0.28 lg/kg bw day for mean and
95th percentile exposure, respectively. Similarly, for protein Cry2Ab2, the highest chronic dietary
exposure in the young population was estimated in toddlers (0.61 lg/kg bw day), and the highest 95th
percentile exposure (1.02 lg/kg bw day) in ‘Other children’. Corresponding highest estimates in adults
were 0.09 lg/kg bw day and 0.49 lg/kg bw day for mean and 95th percentile exposure, respectively.
Overall, in those dietary surveys with the highest chronic exposure the main contributor to the exposure
was soymilk. A conservative exposure scenario to cover possible daily consumption of protein isolates
derived from soybean MON 87751 as protein supplements was carried out. Considering a total protein
concentration of around 90% in these isolates, the concentration of Cry1A.105 and Cry2Ab2 would be
approximately 5 lg/g and 9 lg/g, respectively. Based on the EFSA NDA Panel scientiﬁc opinion on dietary
56 Dossier: Part II – Section 2.4.
57 https://www.efsa.europa.eu/en/applications/gmo/tools
58 Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece,
Hungary, Ireland, Italy, Latvia, the Netherlands, Romania, and Sweden.
59 Example: 100 g of tofu is made with 20.4 g of soybeans; this would result in 0.43 µg of Cry1A.105 per gram of tofu as
compared to 2.1 µg/g in the soybeans.
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reference values for protein (EFSA NDA Panel, 2012), a high consumer of protein (95th percentile) in the
European adult population can consume as much as 1.90 g/kg bw day while in children would reach
4.73 g/kg bw day. Assuming that all consumed protein was from soybean MON 87751 soybean isolates,
the estimated exposure to Cry1A.105 and Cry2Ab2 in adults would be around 11 lg/kg bw day and
19 lg/kg bw day, respectively. In children, the estimated exposure would be around 28 lg/kg bw day
and 47 lg/kg bw day to Cry1A.105 and Cry2Ab2, respectively.
3.4.5.2. Animal dietary exposure60
Daily dietary exposure (DDE) to Cry1A.105 and Cry2Ab2 proteins in soybean MON87751 was
provided by the applicant across different animal species (i.e. broiler, ﬁnishing pig and lactating dairy
cattle), based on estimates, as provided for the EU by OECD (OECD, 2009), for animal body weight,
daily feed intake and inclusion rates (percentage) of soybean meal in animal diets. A conservative
scenario with 100% replacement of conventional soybean (soybean meal) by the GM soybean was
considered. The mean levels of Cry1A.105 and Cry2Ab2 proteins in seeds derived from the ﬁeld trial
study performed in 2012 (see Table 1 in Section 3.2.4) were used as reference to estimate the mean
protein levels in soybean meal,61 calculated to be 1.28-fold higher than in soybean seed, based on the
protein content of soybean meal relative to soybean seed (OECD, 2012), assuming that no protein is
lost during the processing.
Estimated DDEs to the Cry1A.105 based on the consumption of GM soybean meal was 87 lg/kg bw
in broiler, 30 lg/kg bw in dairy cattle and 28 lg/kg bw in ﬁnishing pig.
Estimated DDEs to the Cry2Ab2 based on the consumption of GM soybean meal was 145 lg/kg per
bw in broiler chickens, 49 lg/kg per bw in dairy cattle, and 46 lg/kg per bw in ﬁnishing pig.
The GMO Panel estimated DDEs to Cry1A.105 and Cry2Ab2 proteins in lactating dairy cows, based
on estimates for animal body weight and daily feed intake, as provided for the EU by OECD (OECD,
2009), and estimates for inclusion rates of soybean forage/silage in animal diets, as provided by OECD
consensus document (OECD, 2012) (information that was not provided by the applicant). A
conservative scenario with 100% replacement of conventional soybean (forage/silage) by the GM
soybean was considered. Mean levels of Cry1A.105 and Cry2Ab2 proteins in forage derived from the
ﬁeld trials performed in 2012 (see Table 1 in Section 3.2.4) were used as occurrence data. Estimated
DDEs in lactating dairy cows, based on the consumption of GM soybean forage/silage was 1771 lg/kg
per bw for Cry1A.105 and 108 lg/kg per bw for Cry2Ab2.
3.4.6. Nutritional assessment of GM food and feed62
The intended trait of soybean MON 87751 is insecticide resistance, with no intention to alter the
nutritional parameters. Comparison of the seed and forage composition of soybean MON 87751 with
the conventional counterpart and the non-GM commercial reference varieties did not identify
differences that would require a nutritional assessment as regards food and feed (see Section 3.3.4).
From these data, the GMO Panel concludes that the nutritional impact of soybean MON 87751-derived
food and feed is expected to be the same as that from its conventional counterpart and non-GM
commercial reference varieties.
3.4.7. Post-market monitoring of GM food and feed63
The GMO Panel concludes that soybean MON 87751, as described in this application, is nutritionally
equivalent to and as safe as the conventional counterpart and the non-GM soybean reference varieties
tested, and no post-market monitoring (EFSA GMO Panel, 2011a) of food/feed is considered necessary.
3.4.8. Conclusion on food and feed safety assessment
The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the
proteins Cry1A.105 and Cry2Ab2 expressed in soybean MON 87751, and ﬁnds no evidence that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean MON 87751. Based
on the outcome of the comparative assessment, the nutritional impact of soybean MON 87751-derived
food and feed is expected to be the same as those derived from its conventional counterpart and
60 Dossier: Part II – Section 2.3.
61 Cry1A.105: 230 µg/g; Cry2Ab2: 14 µg/g.
62 Dossier: Part II – Section 1.6.
63 Dossier: Part II – Section 4.
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non-GM commercial reference varieties. The GMO Panel concludes that soybean MON 87751 is
nutritionally equivalent to and as safe as the conventional counterpart and the non-GM reference
varieties tested.
3.5. Environmental risk assessment and monitoring plan
Considering the scope of application EFSA-GMO-NL-2014-121, which excludes cultivation, the ERA
of soybean MON 87751 mainly takes into account: (1) the exposure of microorganisms to recombinant
DNA in the gastrointestinal tract of animals fed GM material and of microorganisms present in
environments exposed to faecal material of these animals (manure and faeces); and (2) the accidental
release into the environment of viable soybean MON 87751 seeds during transportation and processing
(EFSA GMO Panel, 2010a).
3.5.1. Environmental risk assessment
3.5.1.1. Persistence and invasiveness of the GM plant64
Cultivated soybean (G. max) is a species in the subgenus Soja of the genus Glycine. The species
originated from eastern Asia and is a highly domesticated crop, generally unable to survive in the
environment without appropriate management (Lu, 2005).
Occasional feral GM soybean plants may occur outside cultivation areas, but survival is limited
mainly by a combination of low competitiveness, absence of a dormancy phase and susceptibility to
plant pathogens and cold climatic conditions (OECD, 2000). Soybean can grow as volunteers and the
presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean is
intensively cultivated (Celesti-Grapow et al., 2010). However, as for the same reasons mentioned
above, soybean seeds usually do not survive during the winter (Owen, 2005).
Thus, the establishment and survival of feral and volunteer soybean in the EU is currently limited
and transient.
It is unlikely that the intended traits of soybean MON 87751 will provide a selective advantage to
soybean plants, except when they are infested by insect pests that are susceptible to the Cry1A.105
and/or Cry2Ab2 proteins. However, this ﬁtness advantage will not allow the GM plant to overcome
other biological and abiotic factors (described above) limiting plant’s persistence and invasiveness.
Therefore, the presence of the intended traits will not affect the persistence and invasiveness of the
GM plant.
In conclusion, the GMO Panel considers it very unlikely that soybean MON 87751 will differ from
conventional soybean hybrid varieties in its ability to survive until subsequent seasons, or to establish
occasional feral plants under European environmental conditions in case of accidental release into the
environment of viable soybean MON 87751 seeds.
3.5.1.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer of DNA or through vertical gene ﬂow via cross-
pollination from feral plants originating from spilled seeds.
Plant-to-microorganism gene transfer65
Genomic DNA can be a component of food and feed products derived from soybean. It is well
documented that such DNA becomes substantially degraded during processing and digestion in the
human or animal gastrointestinal tract. However, bacteria in the digestive tract of humans and animals,
and in other environments, may be exposed to fragments of DNA, including the recombinant fraction
of such DNA.
Current scientiﬁc knowledge of recombination processes in bacteria suggests that horizontal
transfer of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as
from plants to bacteria) is not likely to occur at detectable frequencies under natural conditions (for
further details, see EFSA, 2009).
The only mechanism known to facilitate horizontal transfer of non-mobile, chromosomal DNA
fragments between to bacterial genomes is homologous recombination. This requires the presence of
64 Dossier: Part II – Section 5.3.1.
65 Dossier: Part II – Section 5.3.2.
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at least two stretches of DNA sequences that are similar in the recombining DNA molecules. In the
case of sequence identity with the transgene itself, recombination would result in gene replacement. In
the case of identity with two or more regions ﬂanking recombinant DNA, recombination could result in
the insertion of additional DNA sequences in bacteria and thus confer the potential for new properties.
Soybean MON 87751 contains genetic elements originating or derived from bacteria (Section 3.2.1).
These are: (1) a plant-optimised, synthetic cry1A.105 gene derived from cry1Ab, cry1F and cry1Ac
coding sequences from B. thuringiensis; and (2) a plant codon-optimised version of the cry2Ab2 gene
from B. thuringiensis.
Bioinformatic analyses of the inserted DNA demonstrated that the bacterial genes cry1A.105, and
cry2Ab2 did not provide sufﬁcient sequence identity to facilitate homologous recombination and
transfer of the recombinant DNA to bacteria in the receiving environments.
In addition to homology-based recombination processes, non-homologous (illegitimate)
recombination that does not require the presence of DNA similarity between the recombining DNA
molecules is theoretically possible. However, the transformation rates for illegitimate recombination were
considered to be 1010-fold lower than for homologous recombination (H€ulter and Wackernagel, 2008;
EFSA, 2009) and have not been detected for GM plants and bacteria, even in studies that have directly
exposed bacteria to high concentrations of GM plant DNA (EFSA, 2009). Due to the plant codon-
optimisation and poor expression of the recombinant cry genes connected to plant promoters as present
on the recombinant DNA of soybean MON 87751, and the presence of natural variants of these genes in
bacteria, it is highly unlikely that the recombinant cry-genes provide a selective advantage to bacterial
recipients in the environment.
In summary, there is no indication for an increased likelihood of horizontal transfer of DNA from
soybean MON 87751 to bacteria. Given the nature of the recombinant DNA, the GMO panel identiﬁed
no safety concern linked to an unlikely but theoretically possible horizontal gene transfer.
Plant-to-plant gene transfer64
The potential for occasional feral soybean MON 87751 plants originating from seed import spills to
transfer recombinant DNA to sexually compatible plants and the environmental consequences of this
transfer were considered.
For plant-to-plant gene transfer to occur, imported GM soybean seeds need to germinate and
develop into plants in areas containing sympatric wild relatives and/or cultivated soybean with
synchronous ﬂowering and environmental conditions favouring cross-pollination. It must be noted that
most soybean MON 87751 seeds are processed in the countries of production or in ports of
importation.
Vertical gene transfer from soybean (G. max) is limited to the species of the subgenus Soja to which
G. max belongs to, as well as the wild relatives G. soja and G. gracilis. Although wild relatives exist
elsewhere, no wild relatives of the subgenus Soja have been reported in Europe (Dorokhov et al., 2004;
Lu, 2005). Therefore, vertical gene transfer from GM soybean is restricted to cultivated soybean (G. max).
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007),
although natural cross-pollination rates can ﬂuctuate signiﬁcantly among different soybean varieties
under particular environmental conditions, such as favourable climate for pollination and an abundance
of pollinators (Caviness, 1966; Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and
Caviness, 1994; Ray et al., 2003; Lu, 2005).
The potential of spilled soybean seeds to establish, grow and produce pollen is extremely low and
transient (see Section 3.5.1.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM soybean plants resulting from seed spillage, and weedy or cultivated soybean
plants is also considered extremely low. Even if cross-pollination would occur, the GMO Panel is of the
opinion that the likelihood of environmental effects as a consequence of the spread of genes from
occasional feral GM soybean plants in Europe will not differ from that of conventional soybean varieties
for the reasons given in Section 3.5.1.1.
3.5.1.3. Interactions of the GM plant with target organisms66
Taking the scope of application EFSA-GMO-NL-2014-121 into account (no cultivation), potential
interactions of occasional feral soybean MON 87751 plants arising from seed import spills with target
organisms are not considered a relevant issue by the GMO Panel.
66 Dossier: Part II – Section 5.3.3.
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3.5.1.4. Interactions of the GM plant with non-target organisms67
Given that environmental exposure of non-target organisms to spilled GM seeds or occasional feral
GM soybean plants arising from spilled soybean MON 87751 seeds is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
soybean, potential interactions of soybean MON 87751 with non-target organisms are not considered
by the GMO Panel to raise any environmental safety concern. Interactions that may occur between the
Cry proteins will not alter this conclusion.
3.5.1.5. Interactions with the abiotic environment and biogeochemical cycles68
Given that environmental exposure to spilled seeds or occasional feral soybean MON 87751 plants
arising from seed import spills is limited, and because ingested proteins are degraded before entering
the environment through faecal material of animals fed GM soybean, potential interactions with the
abiotic environment and biogeochemical cycles are not considered by the GMO Panel to raise any
environmental safety concern.
3.5.2. Post-market environmental monitoring69
The objectives of a PMEM plan according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) to identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from soybean MON 87751, no
case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for soybean MON 87751 includes: (1) the description of
a monitoring approach involving operators (federations involved in import and processing), reporting
to the applicant, via a centralised system, any observed adverse effect(s) of GMOs on human health
and the environment; (2) a coordinating system newly established by EuropaBio for the collection of
information recorded by the various operators; and (3) the review of relevant scientiﬁc publications
retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to
submit a PMEM report on an annual basis and a ﬁnal report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of soybean MON 87751. The GMO Panel agrees with the reporting intervals
proposed by the applicant in its PMEM plan.
In the context of PMEM, the applicant should improve the literature searches according to the GMO
Panel recommendations given in Section 3.1.
3.5.3. Conclusion on the environmental risk assessment and monitoring plan
The GMO Panel concludes that it is unlikely that soybean MON 87751 would differ from conventional
soybean varieties in its ability to persist under European environmental conditions. Considering the scope
of application EFSA-GMO-NL-2014-121, interactions of occasional feral soybean MON 87751 plants with
the biotic and abiotic environment are not considered to be relevant issues. The analysis of horizontal
gene transfer from soybean MON 87751 to bacteria does not indicate a safety concern. Therefore,
considering the introduced traits, the outcome of the comparative analysis, and the routes and levels of
exposure, the GMO Panel concludes that soybean MON 87751 would not raise safety concerns in the
event of accidental release of viable GM soybean seeds into the environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of soybean MON 87751.
67 Dossier: Part II – Section 5.3.4.
68 Dossier: Part II – Section 5.3.6.
69 Dossier: Part II – Section 6.
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4. Conclusions
The GMO Panel was asked to carry out a scientiﬁc assessment of soybean MON 88751 for import,
processing, and food and feed uses in accordance with Regulation (EC) No 1829/2003.
The molecular characterisation data establish that soybean MON 87751 contains a single insert
consisting of one copy of the cry1A.105 and cry2Ab2 expression cassettes. Bioinformatic analyses of
the sequences encoding the newly expressed proteins and other ORFs present within the insert or
spanning the junctions between the insert and genomic DNA do not indicate signiﬁcant similarities to
toxins and allergens. The stability of the inserted DNA and of the introduced insect resistance trait is
conﬁrmed over several generations. The Cry1A.105 and Cry2Ab2 proteins were expressed and the
methodology used to quantify their levels is considered adequate. The protein characterisation data
comparing the structural, biochemical and functional properties of plant- and microbe-derived
Cry1A.105 and Cry2Ab2 proteins indicate that these proteins are equivalent and the microbe-derived
proteins can be used in the safety studies.
The GMO Panel concludes that none of the differences identiﬁed in the agronomic, phenotypic and
compositional characteristics of soybean MON 87751 require further assessment regarding
environmental and food and feed safety.
The GMO Panel does not identify safety concerns regarding the potential toxicity or allergenicity of
the newly expressed Cry1A.105 and Cry2Ab2 proteins, and no evidence that the genetic modiﬁcation
might signiﬁcantly change the overall allergenicity of soybean MON 87751 was found. The nutritional
impact of soybean MON 87751-derived food and feed is expected to be the same as those derived
from its conventional counterpart and non-GM commercial reference varieties. The GMO
Panel concludes that soybean MON 87751-derived food and feed is nutritionally equivalent to and as
safe as the conventional counterpart and the non-GM commercial reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable seeds from soybean MON 87751 into the environment. The PMEM plan
and reporting intervals are in line with the intended uses of soybean MON 87751.
The literature searches did not identify any relevant publications on soybean MON 87751. In the
context of PMEM, the applicant should improve the literature searches according to the GMO
Panel recommendations.
In conclusion, the GMO Panel considers that soybean MON 88751, as described in this application,
is as safe as its conventional counterpart and the tested non-GM soybean varieties with respect to
potential effects on human and animal health and the environment.
Documentation requested and provided to EFSA
1) Letter from the Competent Authority of Netherlands received on 8 October 2014
concerning a request for placing on the market of genetically modiﬁed soybean
MON 87751 submitted by Monsanto Europe S.A./N.V. in accordance with Regulation (EC)
No 1829/2003 (application reference EFSA-GMO-NL-2014-121).
2) Acknowledgement letter dated 15 October 2014 from EFSA to the Competent Authority of
Netherlands.
3) Letter from EFSA to applicant dated 25 November 2014 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 22 December 2014 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 22 January 2015 delivering the ‘Statement of Validity’
of application EFSA-GMO-NL-2014-121 for placing on the market of genetically modiﬁed
soybean MON 87751 submitted by Monsanto Europe S.A./N.V. in accordance with
Regulation (EC) No 1829/2003.
6) Letter from EURL to EFSA dated 26 January 2015 requesting to stop the clock.
7) Letter from EFSA to applicant dated 29 January 2015 requesting additional information and
stopping the clock on behalf of the EURL-GMFF.
8) Letter from EURL to EFSA dated 11 March 2015 requesting to re-start the clock.
9) Letter from EFSA to applicant dated 16 March 2015 re-starting the clock on behalf of the
EURL-GMFF.
10) Letter from EFSA to applicant dated 31 March 2015 requesting additional information and
stopping the clock.
Assessment of soybean MON 87751
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2018;16(8):5346
11) Letter from Applicant to EFSA received 20 May 2015 requesting clariﬁcation.
12) Letter from EFSA to Applicant dated 3 June 2015 providing clariﬁcation.
13) Letter from EFSA to applicant dated 5 June 2015 requesting additional information and
maintaining the clock stopped.
14) Letter from applicant to EFSA received on 1 July 2015 providing additional information.
15) Letter from applicant to EFSA received on 15 July 2015 providing additional information.
16) Letter from EFSA to applicant dated 23 October 2015 re-starting the clock.
17) Letter from EFSA to applicant dated 2 December 2015 requesting additional information
and stopping the clock.
18) Letter from applicant to EFSA received on 9 December 2015 providing additional
information.
19) Letter from EFSA to applicant dated 23 December 2015 requesting additional information
and maintaining the clock stopped.
20) Letter from applicant to EFSA received on 8 February 2016 providing additional
information.
21) Letter from EFSA to applicant dated 11 February 2016 requesting additional information
and maintaining the clock stopped.
22) Letter from EFSA to applicant dated 23 February 2016 requesting additional information
and maintaining the clock stopped.
23) Letter from applicant to EFSA received on 24 February 2016 providing additional
information and requesting clariﬁcation.
24) Letter from applicant to EFSA received on 14 March 2016 providing additional information.
25) Letter from EFSA to applicant dated 18 March 2016 requesting additional information and
maintaining the clock stopped.
26) Letter from applicant to EFSA received on 22 March 2016 providing additional information.
27) Letter from applicant to EFSA received on 29 March 2016 providing additional information.
28) Letter from EFSA to applicant dated 6 April 2016 providing clariﬁcation.
29) Letter from applicant to EFSA received on 7 April 2016 requesting clariﬁcation.
30) Letter from applicant to EFSA received on 20 April 2016 providing spontaneous
information.
31) Letter from EFSA to applicant dated 23 May 2016 providing clariﬁcation.
32) Letter from EFSA to applicant dated 23 May 2016 requesting additional information and
maintaining the clock stopped.
33) Letter from EFSA to applicant dated 20 July 2016 requesting additional information and
maintaining the clock stopped.
34) Letter from applicant to EFSA received on 21 July 2016 providing additional information.
35) Letter from applicant to EFSA received on 22 September 2016 providing additional
information.
36) Letter from EFSA to applicant dated 23 September 2016 re-starting the clock from the 22
September 2016.
37) Letter from EFSA to applicant dated 7 December 2016 requesting additional information
and stopping the clock.
38) Letter from applicant to EFSA received on 20 December 2016 providing additional
information.
39) Letter from EFSA to applicant dated 21 December 2016 re-starting the clock from the 20
December 2016.
40) Letter from EFSA to applicant dated 23 December 2016 requesting additional information
and stopping the clock.
41) Letter by email, from applicant to EFSA received on 23 December 2016 providing
additional information.
42) Letter from EFSA to applicant dated 04 January 2017 re-starting the clock from the 23
December 2016.
43) Letter by e-mail only, from applicant to EFSA received on 2 February 2017 requesting
clariﬁcation.
44) Letter from EFSA to applicant dated 3 February 2017 providing clariﬁcation.
45) Letter from EFSA to applicant dated 10 February 2017 requesting additional information
and stopping the clock.
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46) Letter from EFSA to applicant dated 8 March 2017 requesting additional information and
maintaining the clock stopped.
47) Letter from EFSA to applicant dated 14 March 2017 requesting additional information and
maintaining the clock stopped.
48) Letter from applicant to EFSA received on 11 April 2017 providing additional information.
49) Letter from applicant to EFSA received on 2 May 2017 providing spontaneous information.
50) Letter from EFSA to applicant dated 3 May 2017 requesting additional information and
maintaining the clock stopped.
51) Letter from applicant to EFSA received on 15 May 2017 providing additional information.
52) Letter from applicant to EFSA received on 19 May 2017 providing additional information.
53) Letter from applicant to EFSA received on 31 May 2017 providing additional information.
54) Letter from EFSA to applicant dated 1 June 2017 re-starting the clock from the 31 May 2017.
55) Letter from EFSA to applicant dated 6 July 2017 requesting additional information and
stopping the clock.
56) Letter from EFSA to applicant dated 2 August 2017 requesting additional information and
maintaining the clock stopped.
57) Letter from applicant to EFSA received on 14 August 2017 providing additional information.
58) Letter from applicant to EFSA received on 22 August 2017 providing additional information.
59) Letter from EFSA to applicant dated 22 August 2017 re-starting the clock.
60) Letter from EFSA to applicant dated 25 September 2017 requesting additional information
and stopping the clock.
61) Letter from applicant to EFSA received on 5 October 2017 providing spontaneous
information.
62) Letter from EFSA to applicant dated 23 November 2017 requesting additional information
and maintaining the clock stopped.
63) Letter from applicant to EFSA received on 23 November 2017 providing additional
information.
64) Letter from EFSA to applicant dated 4 December 2017 requesting additional information
and maintaining the clock stopped.
65) Letter from applicant to EFSA received on 4 December 2017 providing additional
information.
66) Letter from applicant to EFSA received on 22 December 2017 providing spontaneous
information.
67) Letter from applicant to EFSA received on 30 January 2018 providing additional
information.
68) Letter from EFSA to applicant dated 31 January 2018 re-starting the clock from the 30
January 2018.
69) Letter from EFSA to applicant dated 7 March 2018 requesting additional information and
stopping the clock.
70) Letter from applicant to EFSA received on 3 May 2018 providing additional information.
71) Letter from EFSA to applicant dated 3 May 2018 re-starting the clock.
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ADF acid detergent ﬁbre
ANOVA analysis of variance
BSA bovine serum albumin
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CTP chloroplast transit peptide
DDE daily dietary exposure
ELISA enzyme-linked immunosorbent assay
ERA environmental risk assessment
FOB functional observational battery
GLP Good Laboratory Practice
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GMO genetically modiﬁed organisms
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
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MCV mean corpuscular volume
NDF neutral detergent ﬁbre
NGS next generation sequencing
OECD Organisation for Economic Co-operation and Development
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